Retrospective Study
Copyright ©The Author(s) 2024.
World J Clin Cases. Jun 16, 2024; 12(17): 3019-3026
Published online Jun 16, 2024. doi: 10.12998/wjcc.v12.i17.3019
Table 1 General data analysis
Factors
Observation group (n = 40)
Control group (n = 40)
χ2/t/Z
P value
Sex0.2080.648
Male25 (62.5)23 (57.5)
Female15 (37.5)17 (42.5)
Age58.68 ± 14.8562.50 ± 17.11-1.0680.289
Course of disease6.50 (5.00, 16.50)6.00 (4.00, 12.00)-0.5600.575
Table 2 Comparison of effective rates, n (%)
Groups
n
Curative effect
Response rate
Marked response rate
Non-response
Response
Marked response
Cure
Observation group400 (0.0)5 (12.5)31 (77.5)4 (10.0)40 (100.0)35 (87.5)
Control group404 (10.0)15 (37.5)19 (47.5)2 (5.0)36 (90.0)21 (52.5)
χ211.667
P value0.11610.001
Table 3 Comparison of Eczema Area and Severity Index and Visual Analogue Scale scores (points)
Groups
n
EASI score
VAS score
Before treatment
After treatment
t value
P value
Before treatment
After treatment
t value
P value
Observation group407.52 ± 3.252.22 ± 1.3012.00206.05 ± 1.541.98 ± 1.0721.7470
Control group407.30 ± 3.963.19 ± 2.529.05806.08 ± 1.722.93 ± 1.2712.4980
t value0.278−2.17−0.069−3.615
P value0.7820.0340.9450.001
Table 4 Comparison of INF-γ, IL-2, IL-4, and IL-10 levels between the case and control groups
ParametersCase groupHealthy control groupt valueP value
INF-γ311.75 ± 136.86399.17 ± 129.35-2.5820.011
IL-235.54 ± 19.1157.25 ± 20.51-4.4790.000
IL-479.40 ± 9.6260.72 ± 9.997.7120.000
IL-1066.00 ± 8.7856.16 ± 6.904.6590.000
Table 5 Comparison of INF-γ, IL-2, IL-4, and IL-10 levels between the observation and control groups before and after treatment
Parameters
Time point
Observation group
Control group
t value
P value
INF-γBefore treatment321.29 ± 135.22302.21 ± 139.530.6210.536
After treatment394.88 ± 115.70a334.38 ± 137.472.130.036
IL-2Before treatment38.15 ± 19.9832.93 ± 18.071.2240.225
After treatment56.51 ± 18.00a47.13 ± 20.04a2.2030.031
IL-4Before treatment81.01 ± 8.7877.79 ± 10.251.5080.136
After treatment61.31 ± 7.60a67.20 ± 9.00a−3.1650.002
IL-10Before treatment65.94 ± 8.8566.06 ± 8.83−0.0630.95
After treatment60.55 ± 11.86a62.00 ± 8.84a−0.6230.535
Table 6 Adverse reaction and recurrence rates, n (%)
Groups
Adverse reactions
Recurrence
Observation group1 (2.5)3 (7.5)
Control group0 (0.0)7 (17.5)
χ21.829
P value1.0000.176